Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revisionNext revision | Previous revision |
| consortium [2013/07/23 14:53] – cooley | consortium [2013/12/18 13:12] (current) – prisca |
|---|
| ===== Other Resources and Documents ===== | ===== Other Resources and Documents ===== |
| |
| | * {{::assay_strategy.docx|Combined Document}} This includes the Strategy Document as one section in a larger paper that is designed to make our overall case for the consortium. |
| | * {{::assaydocument.docx|Skeleton for Proposal}} Original concept for Document to the Agencies. It draws heavily from the CF1 Screening White Paper. |
| | * {{::dmcommunityassaystrategy-p5.pdf|Strategy Document}} which was sent to P5 on Dec 10, 2013 |
| | * {{::dongming_commentsfromandreas_10222013_v2.pdf|Andreas Comments}} to be incorporated in a larger strategy which includes neutrinoless double beta decay. |
| | * {{::dmcommunityassaystrategy-v6pcwithcommentsfrommei.docx|Comments from DongMing}} |
| * {{:orrell_aarm_slides_consortium.pdf|Slides shown by John Orrell}} part of the Discussion of Principles | * {{:orrell_aarm_slides_consortium.pdf|Slides shown by John Orrell}} part of the Discussion of Principles |
| * {{:dura_lbcf.pdf|Low Background Assay}} Slides shown at the DURA meeting by Prisca - includes introduction to the Consortium concept. | * {{:dura_lbcf.pdf|Low Background Assay}} Slides shown at the DURA meeting by Prisca - includes introduction to the Consortium concept. |